Clozapine Extended Release Coating for Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Clozapine's poor solubility and stability pose challenges in developing extended release formulations that maintain therapeutic efficacy and patient compliance, with existing formulations struggling to demonstrate stability under varying temperature and humidity conditions.
Innovation Solution
A stable extended release pharmaceutical composition of Clozapine is developed, comprising Clozapine with pharmaceutically acceptable excipients, featuring a specific particle size and coating layers (acidic, seal, and extended release coatings) to ensure stability and controlled release, formulated as granules, pellets, or tablets for oral administration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If Clozapine is formulated as immediate release tablets, then the drug can be administered, but multiple dosing is required which causes peaks and fluctuations in blood concentration leading to toxicity and poor patient compliance
Solution Approach 1:
The patent segments the drug release process into multiple controlled stages using layered coating systems (seal coat, extended release coating, and additional seal coat) on granules or pellets. This segmentation allows the drug to be released in controlled amounts over extended periods, eliminating the need for multiple dosing while maintaining stable blood concentrations and reducing toxicity risks.
Solution Approach 2:
The patent changes the physical and chemical parameters of the formulation by using micronized Clozapine (D90 less than 10 microns) to improve solubility, and by applying multiple coating layers with specific polymer compositions and thicknesses to control release kinetics. These parameter changes enable extended release profiling while maintaining drug stability.
2Reliability
If extended release formulation is developed to reduce dosing frequency, then patient compliance improves, but stability under varying temperature and humidity conditions becomes challenging
Solution Approach 1:
The patent applies preliminary protective actions by incorporating multiple seal coat layers before and after the extended release coating. These seal coats act as protective barriers that prevent moisture and temperature variations from affecting the drug core and coating integrity, ensuring stability during storage while maintaining the extended release profile.
Solution Approach 2:
The patent uses composite material systems combining different polymers (water-soluble and water-insoluble polymers in the extended release coating, and hydrophilic polymers in seal coats) with specific properties. This composite structure provides both extended release functionality and environmental stability, protecting the drug from humidity and temperature variations.
3Quantity of substance
If Clozapine particle size is reduced to improve solubility, then dissolution rate increases, but manufacturing precision and formulation complexity increase
Solution Approach 1:
The patent changes the particle size parameter by micronizing Clozapine to achieve a D90 of less than 10 microns, which dramatically improves solubility and dissolution rate. This parameter change is achieved through controlled micronization processes that balance solubility enhancement with manufacturability.
Solution Approach 2:
The patent applies local quality enhancement by using micronized Clozapine specifically in the granule or pellet core, while the coating layers provide the extended release functionality. This localized approach to particle size reduction maximizes solubility benefits without requiring the entire formulation to be micronized, simplifying manufacturing.
Data Source
AI summary
Disclosed are stable extended release formulations and pharmaceutical compositions of Clozapine that exhibit improved stability under a variety of conditions, as well as processes for the preparation of such formulations and compositions.